Laboratory issues in the implementation of the marker method.
Two important biomarkers for the identification of growth hormone or IGF-I administration are IGF-I and P-III-P. These substances are determined in plasma or preferably in serum. There are a number of assays on the market for IGF-I but only two for P-III-P. The principles behind these assays and the choice of assays for doping control purposes are discussed. The future possibility of quantification by mass spectrometry is also briefly discussed.
Cowan
David A
DA
Drug Control Centre, Department of Forensic Science and Drug Monitoring, King's College London, London SE1 9NH, United Kingdom. David.cowan@kcl.ac.uk
Bartlett
Christiaan
C
D001681:Biological Assay; D015415:Biomarkers / Q000097:blood; D002138:Calibration; D002624:Chemistry, Clinical / Q000379:methods*; D004300:Doping in Sports; D006801:Humans; D007118:Immunoassay / Q000379:methods; D007334:Insulin-Like Growth Factor I / Q000096:biosynthesis*; D013058:Mass Spectrometry / Q000379:methods; D010446:Peptide Fragments / Q000097:blood*; D011347:Procollagen / Q000097:blood*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D015813:Substance Abuse Detection / Q000379:methods*
D015415:Biomarkers; D010446:Peptide Fragments; D011347:Procollagen; C041876:procollagen Type III-N-terminal peptide; D007334:Insulin-Like Growth Factor I